Trial Profile
Treatment with peginterferon alfa-2a (40KD) (PEGASYS) of chronic hepatitis B patients, who have failed anti-viral treatment. A pilot study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 10 Jun 2010 Actual patient number (50) added as reported by ClinicalTrials.gov.
- 09 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2010 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.